GSK plc Sponsored ADR (GSK)
GSK (GSK) Q2 Earnings and Revenues Beat Estimates
GSK (GSK) came out with quarterly earnings of $1.23 per share, beating the Zacks Consensus Estimate of $1.12 per share. This compares to earnings of $1.09 per share a year ago.
GSK in talks with Trump administration on U.S. drug pricing, CEO says
British drugmaker GSK said on Wednesday it is in talks with the Trump administration about ways to lower U.S. drug costs, becoming the latest pharmaceutical company to acknowledge action under pressure from Washington to rein in prices.
GSK confident of hitting top end of 2025 targets after strong second quarter
GSK PLC (LSE:GSK, NYSE:GSK) said on Wednesday it expects to deliver results at the top end of its guidance for the year after reporting a robust second quarter, fuelled by strong sales in its Specialty Medicines and Vaccines businesses. The pharmaceuticals giant posted sales of £8 billion for the three months to June, up 6% at constant exchange rates.
GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval
GSK's diversified portfolio and strong HIV/specialty medicines offer stability, but growth prospects remain modest amid stiff competition and legal overhangs. Despite a robust pipeline and management's long-term revenue targets, I see limited near-term catalysts to drive significant EPS or share price appreciation. Financials reveal rising inventories and a stretched balance sheet compared to peers, making the current valuation potentially a value trap.
GSK shares rise on $500m drug deal with China's Hengrui
Shares in GSK PLC (LSE:GSK, NYSE:GSK) rose in morning trading after the pharmaceutical group announced a $500 million collaboration with Hengrui Pharma to co-develop up to 12 experimental medicines, in a deal that could be worth as much as $12 billion. The agreement includes global rights (excluding China and a few territories) to HRS-9821, a potential new treatment for chronic obstructive pulmonary disease (COPD).
GSK to make $500m down payment on Chinese licensing deal worth up to $12bn
GSK PLC (LSE:GSK, NYSE:GSK) has agreed to pay $500 million in upfront fees to Chinese drugmaker Hengrui Pharma as part of a wide-ranging collaboration to develop up to 12 experimental medicines in a deal worth up to a potential $12 billion. It is the latest move by the British giant to bolster its pipeline beyond 2031.
Jiangsu Hengrui grants GSK global rights to drug portfolio in $500 million deal
China's Jiangsu Hengrui Pharmaceuticals said on Monday it has agreed to license the global rights of its HRS-9821 drug and 11 other programmes to GlaxoSmithKline Intellectual Property (GSK) for $500 million upfront.
GSK's blood cancer drug gets EU approval for multiple myeloma
British drugmaker GSK said on Thursday the European Union has approved the company's blood cancer drug Blenrep for the treatment of relapsed or refractory multiple myeloma.
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FDA Advisory Panel Votes Against Approval of GSK's Blenrep Combo
GSK stock falls as an FDA panel votes against its Blenrep combo, casting doubt on U.S. approval hopes.
GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt
The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work with the FDA.
GSK shares analysts get out the red pens after FDA knock-back wipes £3bn from drug maker's value
Shares in GSK PLC (LSE:GSK, NYSE:GSK) fell 6% on Thursday, wiping more than £3bn from its market value, after a US advisory committee delivered a serious blow to the drugmaker's oncology ambitions. The Food and Drug Administration's (FDA) Oncology Drugs Advisory Committee (ODAC) voted against approving GSK's multiple myeloma drug Blenrep in two separate phase III trials.
